Related Experiment Video
Updated: Jan 9, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
Combining anxiolytic activity of thymol and trans-ferulic acid: a potential GABAergic intervention
Md Hanif Munshi1,2,3, Noshin Tasnim Yana4,5, Imam Hossen Rakib4,5
1Department of Textile Engineering, Uttara University, Dhaka, 1230, Bangladesh.
Abstract:
Trans-ferulic acid (TFA), a phenolic acid abundant in fruits and cereals, and thymol (THY), a monoterpenoid phenol from thyme oils, are bioactive natural compounds with notable neuropharmacological potential. This study evaluated the combined anxiolytic effects of THY and TFA in Swiss albino mice, focusing on GABAergic mechanisms and pharmacokinetic profiles through in vivo and in silico methods. Mice received vehicle, diazepam (DZP, 2 mg/kg), TFA (50 mg/kg), THY (50 mg/kg), or their combination (THY + TFA; 50 + 50 mg/kg, p.o.). Behavioral assessments in open-field, swing, hole-cross, and light-dark tests indicated that the combined treatment produced more pronounced effects, markedly reducing locomotor and exploratory activity (e.g., square crosses: 25.8 ± 3.7 vs. 94.6 ± 6.2 in control; hole crosses: 3.4 ± 1.8 vs. 15.6 ± 1.9) and increasing time in the light chamber, consistent with anxiolytic-like activity comparable to DZP. Molecular docking targeted gamma-aminobutyric acid A (GABAA) receptor subunits (α2, α3), and ADME/toxicity profiles were analyzed in silico. Docking analysis revealed moderate binding affinities (BAs) to GABAA receptor subunits AF-P26048-F1 (α2 subunit) (- 5.8 kcal/mol) and 8G4X (α3 subunit) (- 5.3 kcal/mol) for TFA and α2 (- 4.7 kcal/mol) and α3 (- 5.6 kcal/mol) for THY, relative to DZP (- 6.9 kcal/mol). These findings suggest that the THY + TFA combination elicits enhanced GABAergic modulation, offering a potential natural therapeutic strategy for anxiety management with reduced toxicity risk. However, formal interaction analyses (e.g., isobologram or two-way ANOVA) are warranted to confirm the combining effect.
More Related Videos
07:51Inhibitory Synapse Formation in a Co-culture Model Incorporating GABAergic Medium Spiny Neurons and HEK293 Cells Stably Expressing GABAA Receptors
Published on: November 14, 2014
07:01Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Related Concept Videos
Anxiolytic Drugs: Benzodiazepines and Buspirone
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Anxiolytic Drugs: Overview
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Sedatives and Hypnotics: Overview
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Sedatives and Hypnotics Drugs: Benzodiazepines
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...